Showing results (571-580 of 587) with videos related to
Sort By:
Pageof 59
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 29, 2016
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillationChern-En Chiang, Tsu-Juey Wu, Kwo-Chang Ueng, et al.Journal of the Chinese Medical Association : JCMA|July 7, 2020
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseasesChern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, et al.Journal of the Chinese Medical Association : JCMA|February 18, 2018
2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseasesChern-En Chiang, Shih-Yi Lin, Tsung-Hsien Lin, et al.Scientific Reports|July 31, 2019
Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer PathwayTzu-Wei Yang, Wei-Hsiang Lee, Siang-Jyun Tu, et al.Acta Cardiologica Sinica|May 31, 2018
In-Hospital Implementation of Evidence-Based Medications is Associated with Improved Survival in Diabetic Patients with Acute Coronary Syndrome - Data from TSOC ACS-DM RegistryKuan-Chun Chen, Wei-Hsian Yin, Chih-Cheng Wu, et al.JACC. Asia|November 7, 2022
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 DiabetesChern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, et al.Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.Pageof 59